The 78,000 X g microsomal fraction of canine ventricular myocardium effected a 20-fold concentration of [3Hjnorepinephrine from a 10-9 M solution. The [3Hinorepinephrine bound was displaced by physiologic concentrations of the beta-adrenergic catecholamines isoproterenol, epinephrine, and norepinephrine, in that order, which is the order of effectiveness of their actions on the force and rate of cardiac contraction. Alpha-adrenergic compounds did not displace [3H]norepinephrine until concentrations four orders of magnitude greater were reached. The beta-adrenergic blocker propranolol displaced at 10 M, whereas the alpha-adrenergic blocker phentolamine was inactive. Metabolites of the catecholamines did not compete for this binding site. It is concluded that, on the basis of specificity and affinity of binding, these microsomal particles are likely to contain the beta-adrenergic receptor.
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For over 20 years the concept of specific alpha and beta receptors for catecholamines has differentiated apparently separable physiologic and pharmacologic actions of norepinephrine, epinephrine, and related compounds (1) . Direct studies of tissue uptake and binding of norepinephrine, however, have been complicated by a number of discrete and apparently very different binding mechanisms for adrenergic agents. In particular, cardiac uptake of specific catecholamines is poorly correlated with the effects of these agents on the rate and force of cardiac action (2) . Uptake is a complex process, which may be separated into neural uptake (2) , neural vesicle (storage granule) uptake (3) , and receptor uptake. Extensive studies have defined the specificities of the neural (2) and neural vesicle (4, 5) (Fig. 1 ).
In the experiments reported, the concentration of [8H1-norepinephrine in the particles was computed as (dpm/g of particles)/(dpm/ml of solution). In the absence of inhibitors this quotient was generally 20 after 2 hr at 370C. In more recent experiments, dilution and further washing of the particles has led to a 20-fold increase in the particle/solution ratio of counts, so that at 2 hr, the concentration of ['H]-norepinephrine in the particles was 400-500 times that in the medium. Several compounds were tested for their ability to inhibit ['H]norepinephrine binding. Agents with direct beta-adrenergic activity on the heart were most effective (Fig. 2,A and  B) . In the range of 106-10-9 M isoproterenol was most potent, with threshold about 10-9 M and 50% inhibition at 1.8 X 10-7 M. Epinephrine and norepinephrine were somewhat less potent. Dopamine and DOPA were significantly less effective.
In contrast to the potency of the direct-acting beta-adrenergic agents, compounds whose beta-adrenergic action is largely due to norepinephrine release and alpha-adrenergic compounds did not compete effectively until much higher concentrations were reached (Fig. 3) significantly only at concentrations above 10-4 M. Phenylephrine was even less potent, with 50% inhibition occurring only at 1.5 X 10-3 M. The alpha-adrenergic agent methoxamine-nd the indirectly beta-active agents mephentermine and ephedrine did not displace at any concentration tested up to5 X 10-3M.
The beta-blocking agent propranolol inhibited binding, whereas the alpha-blocker phentolamine was not active at concentrations below 10-3 M (Fig. 4) (2) . A second uptake process in such tissues is most effectively blocked by 3-O-methylated metabolites such as metanephrine (2) . Binding of norepinephrine in isolated storage granules from bovine splenic nerves and of epinephrine in adrenal medullary granules has also been extensively studied (4, 5) . Again a markedly different specificity was found, with phenethylamine among the most potent inhibitors and isoproterenol less effective. Further, uptake in these storage particles is apparently less specific than that of the beta-receptor, and is blocked equally well by a variety of alpha-and beta-blocking agents (7, 8) .
The structure-activity relationships for interaction of catecholamines with beta-receptors as determined in this system may be considered with reference to Fig. 5 . The ring 3-and 4-hydroxyl groups are required for binding. The ,B-hydroxyl group, though not required, enhances binding. Substitution on the amino group increases binding. These are the precise structural requirements of the beta-adrenergic receptor as determined by pharmacologic studies (9) . Structure-activity considerations for the other norepinephrine binding processes are summarized for contrast in Fig. 5 .
Binding of [3H]epinephrine to liver membranes has been studied, though at concentrations of catecholamines far outside the physiologic range (10) .
In vitro binding of [3H]norepinephrine to cardiac microsomal particles has been previously reported from several laboratories (11) (12) (13) , though the specificity of binding has not been examined. It was shown that the in vitro uptake of [3H]norepinephrine by cardiac microsomes differed markedly from that of the adrenergic storage granules: cardiac microsomal uptake was insensitive to reserpine, which potently blocked nerve granule uptake (11, 13) ; cardiac microsomal uptake was also insensitive to ATP, which stimulated nerve Proc. Nat. Acad. Sci. USA 68 (1971) granule uptake (11, 13) ; after sucrose gradient centrifugation of cardiac microsomes, the fractions that bound [IHInorepinephrine most avidly differed from those containing the norepinephrine storage depots (13) . These findings support the conclusion suggested by the specificity of the in vitro cardiac microsomal binding of ['H]norepinephrine, namely, that this represents the physiologic beta-adrenergic receptor.
